Experts emphasize the need to understand patient journeys, navigate complex value chains, and strategically match the right patients with groundbreaking therapies.
Joe DePinto
Advertisement
Articles by Joe DePinto
Clinicians' enthusiasm for cell and gene therapies is tempered by practical concerns.
Manufacturers can benefit by partnering with an integrated channel services provider that offers both third-party logistics and hub services.
Advertisement
Latest Updated Articles
- External Partners + Integrated Services = Added Value, Efficiency for Specialty Drug Manufacturers
Published: July 26th 2017 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
A Review of Antibody-Drug Conjugates for the Treatment of Urothelial Carcinoma: The Rise of Enfortumab Vedotin
2
Oral Semaglutide Shows Promise for Weight Loss and Cardiometabolic Health
3
Low-Dose Aspirin Linked to Lower Cardiovascular Risk in Type 2 Diabetes
4
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
5
